ATE290880T1 - Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält - Google Patents
Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthältInfo
- Publication number
- ATE290880T1 ATE290880T1 AT01936440T AT01936440T ATE290880T1 AT E290880 T1 ATE290880 T1 AT E290880T1 AT 01936440 T AT01936440 T AT 01936440T AT 01936440 T AT01936440 T AT 01936440T AT E290880 T1 ATE290880 T1 AT E290880T1
- Authority
- AT
- Austria
- Prior art keywords
- inosine
- cytosine
- composition containing
- polycationic peptide
- antigen composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
PCT/EP2001/006437 WO2001093903A1 (en) | 2000-06-08 | 2001-06-07 | Antigenic composition comprising a polycationic peptide and inosine and cytosine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE290880T1 true ATE290880T1 (de) | 2005-04-15 |
Family
ID=3683921
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
AT01936440T ATE290880T1 (de) | 2000-06-08 | 2001-06-07 | Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT0100000A AT410173B (de) | 2000-06-08 | 2000-06-08 | Antigene zusammensetzung |
Country Status (7)
Country | Link |
---|---|
US (2) | US7148191B2 (de) |
EP (1) | EP1286695B1 (de) |
AT (2) | AT410173B (de) |
AU (1) | AU2001262345A1 (de) |
DE (1) | DE60109443T2 (de) |
WO (1) | WO2001093903A1 (de) |
ZA (1) | ZA200209479B (de) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60044146D1 (de) * | 1999-12-22 | 2010-05-20 | Aventis Pasteur | D ihre verwendungen |
RU2413520C2 (ru) | 2000-06-08 | 2011-03-10 | Интерселл Аг | Вакцинная композиция, содержащая иммуностимулирующие олигодезоксинуклеотиды |
AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
ES2307568T3 (es) * | 2000-12-08 | 2008-12-01 | Coley Pharmaceutical Gmbh | Acidos nucleicos de tipo cpg y metodos de uso de los mismos. |
NZ526786A (en) * | 2001-01-03 | 2006-02-24 | Willmar Poultry Co Inc | Methods for removal of lipopolysaccharides (LPS) from vaccines for non-human animals |
JP2004519453A (ja) * | 2001-01-05 | 2004-07-02 | インターツェル・アクチェンゲゼルシャフト | ポリカチオン性化合物の用途 |
US7244438B2 (en) | 2001-01-05 | 2007-07-17 | Intercell Ag | Uses for polycationic compounds |
EP1450821A1 (de) * | 2001-12-07 | 2004-09-01 | Intercell AG | Immunstimulierende oligodeoxynukleotide |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
AU2003214076A1 (en) * | 2002-02-28 | 2003-09-09 | Intercell Ag | Method for isolating ligands eg T cell epitopes |
AU2003243161A1 (en) * | 2002-04-24 | 2003-11-10 | The Regents Of The University Of California | Methods for stimulating tlr/irf3 pathways for inducing anti-microbial, anti-inflammatory and anticancer responses |
AU2003248791A1 (en) * | 2002-07-03 | 2005-11-09 | Oncovir, Inc. | Method for preparation of poly-iclc and uses thereof |
AU2003254585A1 (en) | 2002-07-24 | 2004-02-16 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
EP2402026A3 (de) | 2002-09-13 | 2012-04-18 | Intercell AG | Verfahren zum Isolieren von Hepatitis-C-Virus-Peptiden |
EP1551869A2 (de) | 2002-10-15 | 2005-07-13 | Intercell AG | Bindungdsfaktoren von gruppe b-streptococcus, dafür kodierende nukleinsäuren und verwendungen davon |
AU2003297317A1 (en) * | 2002-12-13 | 2004-07-09 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
AU2004218284B2 (en) | 2003-03-04 | 2009-07-23 | Intercell Ag | Streptococcus pyogenes antigens |
ES2351489T3 (es) * | 2003-03-24 | 2011-02-07 | Intercell Ag | Vacunas mejoradas. |
JP4676426B2 (ja) * | 2003-03-24 | 2011-04-27 | インターツェル・アクチェンゲゼルシャフト | 改良型ワクチン |
EP1608756B1 (de) | 2003-03-31 | 2009-11-18 | Intercell AG | Staphylococcus epidermidis antigene |
WO2004092209A2 (en) | 2003-04-15 | 2004-10-28 | Intercell Ag | S. pneumoniae antigens |
US7438912B2 (en) | 2003-05-07 | 2008-10-21 | Intercell Ag | S.agalactiae antigens I + II |
CN102304527A (zh) | 2003-05-30 | 2012-01-04 | 英特塞尔股份公司 | 肠球菌抗原 |
US8329192B2 (en) | 2003-09-19 | 2012-12-11 | Epitopix Llc | Campylobacter polypeptides and methods of use |
AU2005298742B2 (en) * | 2004-10-29 | 2010-08-12 | Intercell Ag | HCV vaccines for chronic HCV patients |
AU2006214534B2 (en) | 2005-02-14 | 2012-07-19 | Epitopix, Llc | Polypeptides from Staphylococcus aureus and methods of use |
EP2040745B1 (de) | 2006-06-28 | 2012-12-05 | Statens Serum Institut | Expansion des t-zell-repertoirs, um subdominante epitope durch impfung mit antigenen, die als proteinfragmente oder peptidcocktails abgegeben werden, aufzunehmen |
US8529911B2 (en) | 2006-07-07 | 2013-09-10 | Intercell Austria Ag | Small Streptococcus pyogenes antigens and their use |
AU2007295927A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
EP1923069A1 (de) | 2006-11-20 | 2008-05-21 | Intercell AG | Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen |
EP2269625A3 (de) | 2007-01-12 | 2012-08-08 | Intercell AG | Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür |
CN101687900A (zh) * | 2007-03-07 | 2010-03-31 | 恩文塔生物制药公司 | 双链锁核酸组合物 |
WO2008135446A2 (en) | 2007-05-02 | 2008-11-13 | Intercell Ag | Klebsiella antigens |
EP2012122A1 (de) | 2007-07-06 | 2009-01-07 | Medigene AG | Strukturproteine von mutierten Parvoviren als Impfstoffe |
ES2602610T3 (es) | 2007-05-31 | 2017-02-21 | Medigene Ag | Proteína estructural mutada de un parvovirus |
JP2010530229A (ja) | 2007-06-18 | 2010-09-09 | インターセル アーゲー | クラミジア属の抗原 |
EP2197497B1 (de) | 2007-09-27 | 2016-06-01 | ImmunoVaccine Technologies Inc. | Verwendung von liposomen in einem träger mit einer kontinuierlichen hydrophoben phase zur abgabe von polynucleotiden in vivo |
WO2009086640A1 (en) * | 2008-01-10 | 2009-07-16 | Nventa Biopharmaceuticals Corporation | Adjuvant compositions comprising poly-ic and a cationic polymer |
US8241643B2 (en) | 2008-03-17 | 2012-08-14 | Intercell Ag | Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto |
CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
ES2569907T3 (es) | 2008-06-27 | 2016-05-13 | Zoetis Services Llc | Composiciones adyuvantes novedosas |
US20130243779A1 (en) | 2009-02-05 | 2013-09-19 | Intercell Ag | Peptides protective against e. faecalis, methods and uses relating thereto |
US8617574B2 (en) | 2009-02-13 | 2013-12-31 | Valneva Austria Gmbh | Nontypable Haemophilus influenzae antigens |
KR20120005471A (ko) | 2009-03-23 | 2012-01-16 | 이피토픽스, 엘엘씨 | 폴리펩티드 및 그람 양성 폴리펩티드를 함유하는 면역 조성물 및 사용 방법 |
EP2319871A1 (de) | 2009-11-05 | 2011-05-11 | Sanofi-aventis | Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
CA2777237A1 (en) | 2009-10-09 | 2011-04-14 | Sanofi | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP2308896A1 (de) | 2009-10-09 | 2011-04-13 | Sanofi-aventis | Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten |
ES2867375T3 (es) | 2010-09-03 | 2021-10-20 | Valneva Austria Gmbh | Polipéptido aislado de las proteínas de la toxina A y la toxina B de C. difficile y sus usos |
WO2012031760A1 (en) | 2010-09-08 | 2012-03-15 | Medigene Ag | Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto |
WO2012139094A2 (en) | 2011-04-08 | 2012-10-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of developing a vaccine using peptide-poly ic complexes |
CN109675029A (zh) | 2013-09-19 | 2019-04-26 | 硕腾服务有限责任公司 | 油基佐剂 |
HUE063288T2 (hu) | 2015-01-16 | 2024-01-28 | Zoetis Services Llc | Száj és körömfájás betegség vakcina |
US10166280B2 (en) | 2016-06-08 | 2019-01-01 | Epitopix, Llc | Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use |
EP3527223A1 (de) | 2018-02-16 | 2019-08-21 | 2A Pharma AB | Mutiertes parvovirus-strukturprotein |
JP2021513840A (ja) | 2018-02-16 | 2021-06-03 | 2エー ファーマ アーベー | 自己免疫疾患の処置のためのパルボウイルス構造タンパク質 |
MX2021013111A (es) | 2019-05-20 | 2021-11-17 | Valneva Se | Una vacuna de subunidad para el tratamiento o la prevencion de una infeccion del tracto respiratorio. |
US20220233672A1 (en) | 2019-05-31 | 2022-07-28 | Universidad De Chile | An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec) |
US20230372464A1 (en) | 2020-10-07 | 2023-11-23 | Valneva Sweden Ab | Cholera vaccine formulation |
WO2022214678A2 (en) | 2021-04-09 | 2022-10-13 | Valneva Se | Human metapneumo virus vaccine |
WO2023083964A1 (en) | 2021-11-11 | 2023-05-19 | 2A Pharma Ab | Parvovirus structural protein against beta- and gamma-hpv |
WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR6801650D0 (pt) | 1968-08-20 | 1973-03-07 | R Maes | Processo para preparacao de complexos geradores de interferon |
US3725545A (en) * | 1971-02-03 | 1973-04-03 | R Maes | Enhancement of antibody production by nucleic acid-polycation complexes |
CO4600681A1 (es) | 1996-02-24 | 1998-05-08 | Boehringer Ingelheim Pharma | Composicion farmaceutica para la modulacion inmunitaria |
CA2261892A1 (en) | 1996-07-24 | 1998-01-29 | Michelle M. Hanna | Base-protected nucleotide analogs with protected thiol groups |
WO2001078767A2 (en) * | 2000-04-14 | 2001-10-25 | Cistem Biotechnologies Gmbh | Pharmaceutical preparations comprising modified peptides |
AT410173B (de) * | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
-
2000
- 2000-06-08 AT AT0100000A patent/AT410173B/de not_active IP Right Cessation
-
2001
- 2001-06-07 US US10/297,497 patent/US7148191B2/en not_active Expired - Lifetime
- 2001-06-07 WO PCT/EP2001/006437 patent/WO2001093903A1/en active IP Right Grant
- 2001-06-07 DE DE60109443T patent/DE60109443T2/de not_active Expired - Lifetime
- 2001-06-07 EP EP01936440A patent/EP1286695B1/de not_active Expired - Lifetime
- 2001-06-07 AT AT01936440T patent/ATE290880T1/de active
- 2001-06-07 AU AU2001262345A patent/AU2001262345A1/en not_active Abandoned
-
2002
- 2002-11-21 ZA ZA200209479A patent/ZA200209479B/en unknown
-
2006
- 2006-12-12 US US11/609,777 patent/US20070218073A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1286695A1 (de) | 2003-03-05 |
US7148191B2 (en) | 2006-12-12 |
DE60109443D1 (de) | 2005-04-21 |
US20030162738A1 (en) | 2003-08-28 |
DE60109443T2 (de) | 2006-04-13 |
US20070218073A1 (en) | 2007-09-20 |
WO2001093903A1 (en) | 2001-12-13 |
ATA10002000A (de) | 2002-07-15 |
ZA200209479B (en) | 2003-11-21 |
AU2001262345A1 (en) | 2001-12-17 |
EP1286695B1 (de) | 2005-03-16 |
AT410173B (de) | 2003-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE290880T1 (de) | Antigene zusammensetzung die ein polykationisches peptid und inosin und cytosin enthält | |
HUP0303428A2 (hu) | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez | |
TR200102800T2 (tr) | Yeni bileşikler. | |
BR0009206A (pt) | Isolamento e análise de proteina | |
HUP0004639A2 (hu) | Chlamydia fehérje, génszekvencia és ezek alkalmazása | |
ATE404583T1 (de) | Funktionelle antagonisten von hedgehog-aktivität | |
TR200003513T2 (tr) | Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları | |
AR038568A1 (es) | Anticuerpos anti-a beta y su uso | |
DE60037450D1 (de) | Funf-helix protein | |
CY1117746T1 (el) | Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna | |
SE0002102D0 (sv) | Chemical compound | |
YU9403A (sh) | Anti-dualna antitela integrina, kompozicije, postupci i primene | |
DE60033431D1 (de) | Chimärische natriuretische peptide | |
ATE247484T1 (de) | Von der telomerase abgeleitete antigene peptide | |
NI200800193A (es) | Anticuerpos humanos anti-il-23, composiciones, métodos y usos. | |
ATE267211T1 (de) | Impfstoff gegen hpv | |
TR199900267T2 (xx) | GnRH-L�kotoksin kimeralar�. | |
BR0114646A (pt) | anticorpos anti-lt-beta-r humanizados | |
ATE347600T1 (de) | Gruppe b-streptococcus antigene | |
DE69111440D1 (de) | Methoden und zusammensetzungen zur impfung gegen hiv. | |
ATE384119T1 (de) | Isoprenoidproduktion | |
DE50112802D1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
TR200103339T2 (tr) | Geliştirilmiş çözülürlük özelliklerine sahip yeni LHRH-antagonistleri. | |
WO1999004011A3 (en) | Hiv-1 group o antigens and uses thereof | |
DE69938725D1 (de) | Monoklonale antikörper gegen das protein g3bp und deren verwendungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1286695 Country of ref document: EP |